GlassScriptPhysician profile
Krina Chavda
NPI 1831424142
$15,235.38
in general payments reported to CMS, 2019-2025
35 companies · $1,837 in 2025
The $1,837 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,759 · 2020: $1,024 · 2021: $3,566 · 2022: $1,928 · 2023: $1,932 · 2024: $2,190 · 2025: $1,837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,562 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,562.32 |
| Education | $396.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,616.14 | 2019-2025 | |
| Abbvie INC. | $1,812.18 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $1,725.87 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,448.40 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $940.97 | 2019-2025 | Nemluvio, Epsolay |
| Pfizer INC. | $687.26 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $594.02 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Regeneron Healthcare Solutions, INC. | $545.39 | 2019-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $457.65 | 2019-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $452.22 | 2019-2025 | |
| Epsfl, LLC | $411.35 | 2023 | |
| Amgen INC. | $341.21 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $240.03 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $213.64 | 2022-2025 | Sotyktu |
| Encore Dermatology INC. | $190.16 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $181.99 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $165.10 | 2019-2021 | |
| Smith+Nephew, INC. | $143.21 | 2023 | Grafix |
| Arcutis Biotherapeutics, INC. | $139.32 | 2023-2024 | Zoryve |
| Biofrontera INC. | $132.92 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Incyte Corporation | $104.45 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $95.25 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 | |
| Genentech USA, INC. | $90.32 | 2019-2024 | Xolair |
| Almirall LLC | $75.09 | 2021-2024 | Seysara |
| Celgene Corporation | $72.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.86 | 2022-2023 | Spevigo |
| Dermira, INC. | $53.63 | 2020 | |
| Sebela Pharmaceuticals INC. | $45.22 | 2022-2023 | Naftin, Pramosone |
| Organogenesis INC. | $20.06 | 2023 | Puraply |
| Promius Pharma LLC | $19.88 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.30 | 2020 | |
| Botanix Sb INC | $17.77 | 2025 | Sofdra |
| Tempus Ai, INC | $16.33 | 2024 | Merlin Test |
| Lnhc, INC | $14.72 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krina Chavda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.